Cambridge Investment Research Advisors, Inc. Crispr Therapeutics Ag Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.9 Billion
- Q4 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 34,275 shares of CRSP stock, worth $1.34 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34,275
Previous 24,302
41.04%
Holding current value
$1.34 Million
Previous $1.14 Million
18.13%
% of portfolio
0.0%
Previous 0.0%
Shares
25 transactions
Others Institutions Holding CRSP
# of Institutions
488Shares Held
64.1MCall Options Held
1.64MPut Options Held
1.93M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.97MShares$352 Million3.09% of portfolio
-
Capital International Investors Los Angeles, CA8.74MShares$343 Million0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.81MShares$149 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$109 Million0.0% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.75MShares$108 Million0.07% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.06B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....